<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>Diamond不是王老五 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-17T20:36:49+08:00</updated>
  <subtitle>定期更新免疫肿瘤数据、机制等，以及个人喜欢并翻译的外文书籍。本公众号文章均为原创，仅代表个人观点，与所供职公司无关，仅做学术交流，无任何商业目的</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>2021 ASCO GI (2)</title>
    <updated>2021-01-17T13:21:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-17:/s/s6D_S2u6BIMx0eyhP6qFGA</id>
    <link href="https://mp.weixin.qq.com/s/s6D_S2u6BIMx0eyhP6qFGA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2021 ASCO GI</title>
    <updated>2021-01-16T09:50:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/4M_7krVmAgjaPJtiHEexVQ</id>
    <link href="https://mp.weixin.qq.com/s/4M_7krVmAgjaPJtiHEexVQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Next Generation Sequencing and Emerging Targets</title>
    <updated>2021-01-16T09:50:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/VjMfbhFV7hrbh4qDKCLo9Q</id>
    <link href="https://mp.weixin.qq.com/s/VjMfbhFV7hrbh4qDKCLo9Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>美国FDA关于PD-(L)1难治/耐药的部分考量</title>
    <updated>2020-12-28T07:42:03+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-28:/s/yj9j8Cxu3xof4mVj2aTdOg</id>
    <link href="https://mp.weixin.qq.com/s/yj9j8Cxu3xof4mVj2aTdOg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>免疫联合治疗特征</title>
    <updated>2020-12-13T13:34:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-13:/s/f_1brLLxNt1FbQUjJat8wQ</id>
    <link href="https://mp.weixin.qq.com/s/f_1brLLxNt1FbQUjJat8wQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>III期研究基础来自动物模型？</title>
    <updated>2020-12-07T07:41:20+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/RXDeB4gGSbH61S38B2ffNw</id>
    <link href="https://mp.weixin.qq.com/s/RXDeB4gGSbH61S38B2ffNw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>学术挑刺贴</title>
    <updated>2020-12-05T17:01:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-05:/s/g1k2H3exarlW9TXF3B1hqg</id>
    <link href="https://mp.weixin.qq.com/s/g1k2H3exarlW9TXF3B1hqg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>信达肝癌幻灯分享</title>
    <updated>2020-12-02T09:44:33+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/yWkCna7JMxDfAe6UUvzIjw</id>
    <link href="https://mp.weixin.qq.com/s/yWkCna7JMxDfAe6UUvzIjw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020 ESMO ASIA：如何应对三代EGFR-TKI耐药</title>
    <updated>2020-11-30T06:45:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/5hgS-BuUpjq10lz3DlUl9A</id>
    <link href="https://mp.weixin.qq.com/s/5hgS-BuUpjq10lz3DlUl9A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>对标罗氏，信达的肝癌组合疗效如何？</title>
    <updated>2020-11-22T12:20:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-22:/s/rHWtEOEj4qYGbq2MZYg7Tw</id>
    <link href="https://mp.weixin.qq.com/s/rHWtEOEj4qYGbq2MZYg7Tw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>疾病进展或死亡风险降低50%！基石公布舒格利单抗NSCLC详细数据</title>
    <updated>2020-11-21T18:16:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-21:/s/zmwE_3sYk_Bzmxtp9Nzf-w</id>
    <link href="https://mp.weixin.qq.com/s/zmwE_3sYk_Bzmxtp9Nzf-w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>